Opendata, web and dolomites

Tuberculini SIGNED

A novel in-vitro diagnostic test for drug-resistant tuberculosis and a personalized antibiotic treatment plan.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Tuberculini project word cloud

Explore the words cloud of the Tuberculini project. It provides you a very rough idea of what is the project "Tuberculini" about.

proprietary    ngs    antibiotic    infectious    clemedi    hain    founded    detect    ivds    person    mortalities    240k    machine    business    opportunity    tests    tb    causes    minimum    12    antibiotics    company    rapid    competitors    samples    becton    lifescience    uses    inability    sme    generation    smei    resistance    learning    analyze    spin    susceptibility    diagnosed    antimicrobial    resistant    obtaining    amplify    positively    plan    matching    battle    annotate    tuberculini    addressable    2050    advantage    2019    diagnostic    total    financial    diagnose    profiles    off    commercial    swiss    world    feasibility    data    detection    university    death    disease    cepheid    sequencing    prescription    ivd    73    primers    solution    market    caused    significantly    dickinson    infections    larger    followed    patient    companies    diseases    24    therapy    personalized    vs    zurich    p1    competitive    contributor    vision    algorithms    vitro    tuberculosis    dna    platform    mdr    valued    hours    drug    ag    advice    10k    48    global   

Project "Tuberculini" data sheet

The following table provides information about the project.

Coordinator
CLEMEDI AG 

Organization address
address: WAGISTRASSE 12
city: SCHLIEREN
postcode: CH-8952
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CLEMEDI AG CH (SCHLIEREN) coordinator 50˙000.00

Map

 Project objective

Company: Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.

Need to address: Antimicrobial resistant infections will be among the world’s leading causes of death by 2050. Multi-drug-resistant tuberculosis (MDR-TB) is a large contributor to death by antimicrobial resistance, with over 240k global mortalities (of which 10k in Europe) per year. Many of these are caused by the inability to detect resistance and antibiotic susceptibility in the diagnostic process.

Solution: Clemedi is developing a unique platform to rapidly diagnose drug-resistant infectious diseases, including MDR-TB, and rapidly provide a matching therapy plan. The platform uses proprietary primers to amplify specific DNA from patient samples, followed by next-generation sequencing (NGS) analysis. Machine-learning algorithms are then used to annotate the NGS data, and determine susceptibility or resistance based on DNA-profiles to provide a focused advice on antibiotic therapy, within 24-48 hours after obtaining a patient’s sample.

Business opportunity: The minimum total addressable market for Clemedi (i.e. every person that needs to be diagnosed for MDR-TB) is valued at €73.7 M. Competitors are companies that also develop IVDs for rapid detection of MDR-TB, such as Hain Lifescience, Cepheid and Becton-Dickinson. The main competitive advantage of Tuberculini is its ability to analyze susceptibility for a significantly larger number of antibiotics (12 vs. 1-5). Only this can positively impact disease management.

Feasibility study: Financial support from the SMEi P1 will be used to assess the technical and commercial feasibility of Tuberculini, Clemedi’s IVD for MDR-TB.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUBERCULINI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUBERCULINI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More